Jcovden, cjepivo protiv COVID-19 (Ad26.CoV2-S [rekombinantni])
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
| Name | Jcovden, cjepivo protiv COVID-19 (Ad26.CoV2-S [rekombinantni]) |
|---|---|
| Former Name | COVID-19 Vaccine Janssen |
| Active Substance | Adenovirus tipa 26 koji kodira glikoprotein šiljka virusa SARS-CoV-2 (Ad26.COV2-S) |
| Prescription | na recept |
| Type of prescription | neponovljivi recept |
| Distribution | u ljekarni |
| ATC Code | J07BN02 |
| Medicinal product marketed in the Croatia | Trajni prekid opskrbe |
| Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
| Link to the European Medicines Agency's (EMA) product information | download |
| Link to the European Commission's (EC) decisions | download |
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od imunosne trombocitopenije (ITP) i venske tromboembolije (VTE) uz primjenu cjepiva COVID-19 Vaccine Janssen | 13.10.2021 | Janssen Cilag International N.V. |
| Pismo zdravstvenim radnicima o kontraindikaciji primjene cjepiva COVID-19 Vaccine Janssen u osoba koje su prethodno imale sindrom kapilarnog curenja i nove informacije o sindromu tromboze praćene trombocitopenijom | 19.07.2021 | Janssen Cilag International N.V. |
| Pismo zdravstvenim radnicima o povezanosti primjene cjepiva COVID-19 Vaccine Janssen i pojave tromboze u kombinaciji s trombocitopenijom | 26.04.2021 | Janssen Cilag International N.V. |
